Quoin Pharmaceuticals FY 2024 GAAP EPS $(1.91) Beats $(2.10) Estimate, Quoin Had Approximately $14.1M In Cash, Cash Equivalents And Marketable That Is Expected To Fund The Company's Operations Into Q2 Of 2026

Benzinga · 03/13 11:37
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.91) per share which beat the analyst consensus estimate of $(2.10) by 9.05 percent.